148 related articles for article (PubMed ID: 33693986)
1. Associations of Pretreatment Physical Status Parameters with Tolerance of Concurrent Chemoradiation and Survival in Patients with Non-small Cell Lung Cancer.
Voorn MJJ; Aerts LPA; Bootsma GP; Bezuidenhout JB; van Kampen-van den Boogaart VEM; Bongers BC; de Ruysscher DK; Janssen-Heijnen MLG
Lung; 2021 Apr; 199(2):223-234. PubMed ID: 33693986
[TBL] [Abstract][Full Text] [Related]
2. Stage III Non-Small Cell Lung Cancer in the elderly: Patient characteristics predictive for tolerance and survival of chemoradiation in daily clinical practice.
Driessen EJ; Bootsma GP; Hendriks LE; van den Berkmortel FW; Bogaarts BA; van Loon JG; Dingemans AC; Janssen-Heijnen ML
Radiother Oncol; 2016 Oct; 121(1):26-31. PubMed ID: 27522577
[TBL] [Abstract][Full Text] [Related]
3. Radiotherapy Dose and Induction Chemotherapy Cycles Are Associated With Prognosis and Toxicity Risk: A Retrospective Study of 227 Patients With Unresectable Stage III Non-Small-Cell Lung Cancer.
Chen L; Hou Y; Xia Y; Chang L; Diao X; Wang L; Li L; Long Q; Liu Y; Liu Y; Li W
Technol Cancer Res Treat; 2020; 19():1533033820951802. PubMed ID: 33073689
[TBL] [Abstract][Full Text] [Related]
4. Standard-dose versus high-dose conformal radiotherapy with concurrent and consolidation carboplatin plus paclitaxel with or without cetuximab for patients with stage IIIA or IIIB non-small-cell lung cancer (RTOG 0617): a randomised, two-by-two factorial phase 3 study.
Bradley JD; Paulus R; Komaki R; Masters G; Blumenschein G; Schild S; Bogart J; Hu C; Forster K; Magliocco A; Kavadi V; Garces YI; Narayan S; Iyengar P; Robinson C; Wynn RB; Koprowski C; Meng J; Beitler J; Gaur R; Curran W; Choy H
Lancet Oncol; 2015 Feb; 16(2):187-99. PubMed ID: 25601342
[TBL] [Abstract][Full Text] [Related]
5. Prediction of acute toxicity grade ≥ 3 in patients with locally advanced non-small-cell lung cancer receiving intensity modulated radiotherapy and concurrent low-dose Cisplatin.
Uyterlinde W; Belderbos J; Baas C; van Werkhoven E; Knegjens J; Baas P; Smit A; Rikers C; van den Heuvel M
Clin Lung Cancer; 2013 Sep; 14(5):541-8. PubMed ID: 23835165
[TBL] [Abstract][Full Text] [Related]
6. Handgrip weakness, low fat-free mass, and overall survival in non-small cell lung cancer treated with curative-intent radiotherapy.
Burtin C; Bezuidenhout J; Sanders KJC; Dingemans AC; Schols AMWJ; Peeters STH; Spruit MA; De Ruysscher DKM
J Cachexia Sarcopenia Muscle; 2020 Apr; 11(2):424-431. PubMed ID: 32045108
[TBL] [Abstract][Full Text] [Related]
7. Factors Associated With Early Mortality in Patients Treated With Concurrent Chemoradiation Therapy for Locally Advanced Non-Small Cell Lung Cancer.
Warner A; Dahele M; Hu B; Palma DA; Senan S; Oberije C; Tsujino K; Moreno-Jimenez M; Kim TH; Marks LB; Rengan R; De Petris L; Ramella S; De Ruyck K; De Dios NR; Bradley JD; Rodrigues G
Int J Radiat Oncol Biol Phys; 2016 Mar; 94(3):612-20. PubMed ID: 26867890
[TBL] [Abstract][Full Text] [Related]
8. Optimizing Survival of Patients With Marginally Operable Stage IIIA Non-Small-Cell Lung Cancer Receiving Chemoradiotherapy With or Without Surgery.
Yang KL; Chang YC; Ko HL; Chi MS; Wang HE; Hsu PS; Lin CC; Yeh DY; Kao SJ; Jiang JS; Chi KH
Clin Lung Cancer; 2016 Nov; 17(6):550-557. PubMed ID: 27378175
[TBL] [Abstract][Full Text] [Related]
9. Acute severe radiation pneumonitis among non-small cell lung cancer (NSCLC) patients with moderate pulmonary dysfunction receiving definitive concurrent chemoradiotherapy: Impact of pre-treatment pulmonary function parameters.
Zhou Y; Yan T; Zhou X; Cao P; Luo C; Zhou L; Xu Y; Liu Y; Xue J; Wang J; Wang Y; Lu Y; Liang B; Gong Y
Strahlenther Onkol; 2020 Jun; 196(6):505-514. PubMed ID: 31828393
[TBL] [Abstract][Full Text] [Related]
10. Guideline-concordant Care Improves Overall Survival for Locally Advanced Non-Small-cell Lung Carcinoma Patients: A National Cancer Database Analysis.
Ahmed HZ; Liu Y; O'Connell K; Ahmed MZ; Cassidy RJ; Gillespie TW; Patel P; Pillai RN; Behera M; Steuer CE; Owonikoko TK; Ramalingam SS; Curran WJ; Higgins KA
Clin Lung Cancer; 2017 Nov; 18(6):706-718. PubMed ID: 28601387
[TBL] [Abstract][Full Text] [Related]
11. A population-based comparative effectiveness study of chemoradiation regimens and sequences in stage III non-small cell lung cancer.
Harris JP; Patel MI; Loo BW; Wakelee HA; Diehn M
Lung Cancer; 2017 Jun; 108():173-182. PubMed ID: 28625632
[TBL] [Abstract][Full Text] [Related]
12. Prognostic factors in stage III non-small-cell lung cancer.
Ademuyiwa FO; Johnson CS; White AS; Breen TE; Harvey J; Neubauer M; Hanna NH
Clin Lung Cancer; 2007 Sep; 8(8):478-82. PubMed ID: 17922971
[TBL] [Abstract][Full Text] [Related]
13. Early Weight Loss during Chemoradiotherapy Has a Detrimental Impact on Outcome in NSCLC.
Sanders KJ; Hendriks LE; Troost EG; Bootsma GP; Houben RM; Schols AM; Dingemans AM
J Thorac Oncol; 2016 Jun; 11(6):873-9. PubMed ID: 26940529
[TBL] [Abstract][Full Text] [Related]
14. Association between intensity modulated radiotherapy and survival in patients with stage III non-small cell lung cancer treated with chemoradiotherapy.
Koshy M; Malik R; Spiotto M; Mahmood U; Rusthoven CG; Sher DJ
Lung Cancer; 2017 Jun; 108():222-227. PubMed ID: 28625640
[TBL] [Abstract][Full Text] [Related]
15. Neoadjuvant chemoradiation and surgery improves survival outcomes compared with definitive chemoradiation in the treatment of stage IIIA N2 non-small-cell lung cancer.
Darling GE; Li F; Patsios D; Massey C; Wallis AG; Coate L; Keshavjee S; Pierre A; De Perrot M; Yasufuku K; Cypel M; Waddell T
Eur J Cardiothorac Surg; 2015 Nov; 48(5):684-90; discussion 690. PubMed ID: 25567960
[TBL] [Abstract][Full Text] [Related]
16. Definitive treatment patterns and survival in stage II non-small cell lung cancer.
Yan SX; Qureshi MM; Suzuki K; Dyer M; Truong MT; Litle V; Mak KS
Lung Cancer; 2018 Oct; 124():135-142. PubMed ID: 30268452
[TBL] [Abstract][Full Text] [Related]
17. Phase 1 Trial of Pembrolizumab Administered Concurrently With Chemoradiotherapy for Locally Advanced Non-Small Cell Lung Cancer: A Nonrandomized Controlled Trial.
Jabbour SK; Berman AT; Decker RH; Lin Y; Feigenberg SJ; Gettinger SN; Aggarwal C; Langer CJ; Simone CB; Bradley JD; Aisner J; Malhotra J
JAMA Oncol; 2020 Jun; 6(6):848-855. PubMed ID: 32077891
[TBL] [Abstract][Full Text] [Related]
18. Combined modality trials of the Cancer and Leukemia Group B in stage III non-small-cell lung cancer: analysis of factors influencing survival and toxicity.
Socinski MA; Zhang C; Herndon JE; Dillman RO; Clamon G; Vokes E; Akerley W; Crawford J; Perry MC; Seagren SL; Green MR
Ann Oncol; 2004 Jul; 15(7):1033-41. PubMed ID: 15205196
[TBL] [Abstract][Full Text] [Related]
19. Nutrition during trimodality treatment in stage III non-small cell lung cancer: not only important for underweight patients.
van der Meij BS; Phernambucq EC; Fieten GM; Smit EF; Paul MA; van Leeuwen PA; Oosterhuis JW
J Thorac Oncol; 2011 Sep; 6(9):1563-8. PubMed ID: 21642868
[TBL] [Abstract][Full Text] [Related]
20. Feasibility and efficacy of salvage lung resection after definitive chemoradiation therapy for Stage III non-small-cell lung cancer.
Shimada Y; Suzuki K; Okada M; Nakayama H; Ito H; Mitsudomi T; Saji H; Takamochi K; Kudo Y; Hattori A; Mimae T; Aokage K; Nishii T; Tsuboi M; Ikeda N
Interact Cardiovasc Thorac Surg; 2016 Dec; 23(6):895-901. PubMed ID: 27543652
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
